Nivolumab Monotherapy Dosing for Refractory Hodgkin Lymphoma
For adult patients with refractory classical Hodgkin lymphoma, nivolumab monotherapy should be administered at 3 mg/kg intravenously every 2 weeks, or alternatively 240 mg IV every 2 weeks or 480 mg IV every 4 weeks, until disease progression or unacceptable toxicity. 1
FDA-Approved Dosing Regimens
The FDA has approved multiple dosing schedules for nivolumab in classical Hodgkin lymphoma (cHL) that relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin 1, 2:
All three regimens are FDA-approved and considered equivalent in efficacy and safety based on pharmacokinetic modeling 1. The flat dosing regimens were established through population pharmacokinetic analyses across multiple tumor types and do not reflect the original pivotal trial dosing 3.
Evidence from Pivotal Trials
The approval was based on the CheckMate 205 trial, which used 3 mg/kg IV every 2 weeks in 243 patients with relapsed/refractory cHL after autologous HSCT failure 5, 4. This study demonstrated:
- Overall response rate: 71.2% (95% CI: 65.1-76.8%) 5
- Complete response rate: 21.4% (95% CI: 16.4-27.1%) 5
- Median progression-free survival: 15.1 months 5
- 5-year overall survival: 71.4% 5
The CheckMate 039 phase 1b study, which established the 3 mg/kg dose, showed an 87% objective response rate in 23 heavily pretreated patients 6.
Treatment Duration
Continue nivolumab until disease progression, unacceptable toxicity, or death 3, 1. Key considerations include:
- Treatment can continue beyond initial RECIST-defined progression in selected patients who demonstrate clinical benefit and tolerable adverse events 3
- Patients achieving complete response for ≥1 year may discontinue therapy and resume upon relapse; all 3 patients who did this in CheckMate 205 achieved objective response upon retreatment 5
- Median duration of response in pivotal trials was 18.2 months (95% CI: 14.7-26.1) 5
Infusion Parameters
Administer as a 60-minute intravenous infusion 1. Pharmacokinetic studies demonstrate that a 30-minute infusion produces comparable drug exposure to 60-minute infusion, though the 60-minute duration remains standard 1.
Low-Dose Alternative (Investigational)
Recent data suggest 40 mg flat dosing (median 0.58 mg/kg) may provide comparable efficacy and safety to standard dosing 7:
- 5-year PFS: 26.8% vs 22.1% (p=0.77) compared to standard dose 7
- 5-year OS: 95.7% vs 93.3% (p=0.33) 7
- Similar adverse event rates 7
However, this remains investigational and is not FDA-approved 7.
Common Pitfalls to Avoid
Do not use nivolumab in pediatric patients under 12 years - only pembrolizumab has been studied in this population 8. For patients ≥12 years, nivolumab exposures are comparable to adults at recommended dosing 1.
Exercise extreme caution with allogeneic HSCT after nivolumab due to increased risk of severe/hyperacute graft-versus-host disease, immune-mediated adverse reactions, and transplant-related mortality 2. Limited data exist for nivolumab use following allogeneic transplantation 8.
Monitor for late-onset pulmonary toxicity - in Japanese patients, pulmonary adverse events occurred ≥17 months after starting nivolumab in some cases, requiring continued vigilance 9.
Grade 3-4 adverse events occur in approximately 22% of patients, with the most common being neutropenia and elevated lipase (5% each) 4. Immune-related adverse events include thyroiditis/hypothyroidism (>10%), rash, pneumonitis, hepatitis, and colitis (1-5%) 3.